Neuronetics, Inc.
NASDAQ:STIMMedical - Diagnostics & Research
+$0.00 today
- Market cap
- $96.38M
- Beta
- 1.04
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.53
Volume 1.66M
Average 2.44M
Income Statement
Follow revenue through to earnings.
Revenue
$149.16M
FY 2025 · Annual
+99.2% YoYOperating Income
-$31.44M
FY 2025 · Annual
Net Income
-$39.00M
FY 2025 · Annual
Income Statement
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.31M | 65.21M | 71.35M | 74.89M | 149.16M |
| Cost of Revenue | 11.65M | 15.48M | 19.64M | 20.73M | 76.85M |
| Gross Profit | 43.66M | 49.72M | 51.71M | 54.16M | 72.31M |
| Gross Margin | 78.9% | 76.3% | 72.5% | 72.3% | 48.5% |
| Research & Development | 7.92M | 9.34M | 9.52M | 12.77M | 6.58M |
| Selling, General & Admin | 63.3M | 75.5M | 72.74M | 75.95M | 97.16M |
| Operating Expenses | 71.22M | 84.83M | 82.26M | 88.72M | 103.74M |
| Depreciation & Amortization | 1.06M | 1.65M | 2.01M | 2.07M | 3.47M |
| EBITDA | (26.81M) | (31.96M) | (22.76M) | (34.37M) | (27.12M) |
| EBITDA Margin | -48.5% | -49.0% | -31.9% | -45.9% | -18.2% |
| Operating Income | (27.56M) | (35.11M) | (30.55M) | (34.56M) | (31.44M) |
| Operating Margin | -49.8% | -53.8% | -42.8% | -46.2% | -21.1% |
| Interest Income | 0 | 0 | 24K | 0 | 0 |
| Interest Expense | 3.3M | 3.6M | 5.42M | 7.29M | 8.42M |
| Other Income / Expenses | (3.61M) | (2.1M) | 365K | (9.18M) | (7.56M) |
| Income Before Tax | (31.17M) | (37.21M) | (30.19M) | (43.74M) | (39M) |
| Pre-Tax Margin | -56.4% | -57.1% | -42.3% | -58.4% | -26.1% |
| Income Tax Expense | 0 | 0 | (24K) | (14K) | 0 |
| Net Income | (31.19M) | (37.16M) | (30.19M) | (43.71M) | (39M) |
| Net Margin | -56.4% | -57.0% | -42.3% | -58.4% | -26.1% |
| EPS (Basic) | (1.22) | (1.38) | (1.05) | (1.38) | (0.59) |
| EPS (Diluted) | (1.22) | (1.38) | (1.05) | (1.38) | (0.59) |
| 25.48M | 26.9M | 28.66M | 31.73M | 65.95M | |
| 25.48M | 26.9M | 28.66M | 31.73M | 65.95M |
STIM Earnings Waterfall · TTM
NASDAQ:STIM · Revenue to Net Income
Key Ratios
Analysis
$151.6M of revenue converted into -$37.1M of net income for the selected period. Gross margin is 47.8% and net margin is -24.8%, showing how much revenue survives after costs and taxes. EPS is $-0.54, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 424B5 | 424B5 filing | Nov 12, 2026 | |
| 8-K/A | 8-K/A filing | Nov 12, 2026 | |
| 8-K | Current report | Nov 10, 2026 |
How much revenue does STIM generate?
Neuronetics, Inc. (STIM) reported $149.16M of revenue in fiscal 2025.
Is STIM profitable?
Neuronetics, Inc. (STIM) reported -$39.00M of net income, with a net margin of -26.1%.
Continue the stock analysis
Jump to another research area for this company.